The antiandrogenic effect of finasteride against a mutant androgen receptor

Cancer Biology and Therapy

Volumn 11, Issue 10, 2011, Pages 902-909

  Wu, Yue ^a   Chhipa, Rishi Raj ^a   Zhang, Haitao ^b   Ip, Clement ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Androgen receptor; Antagonistic effect; DHT; Finasteride; Mutant AR; Peroxiredoxin 1; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; BICALUTAMIDE; FINASTERIDE; MUTANT PROTEIN; PEROXIREDOXIN 1;

ANDROGEN DEPRIVATION THERAPY; ANTIANDROGENIC EFFECT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL GROWTH; CELL STRAIN C4 2; CELL STRAIN LNCAP; CELL STRAIN VCAP; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HUMAN; HUMAN CELL; INHIBITION KINETICS; MALE; PROSTATE CANCER; PROTEIN EXPRESSION; WILD TYPE;

ANDROGEN ANTAGONISTS; ANDROGEN RECEPTOR ANTAGONISTS; ANILIDES; CELL LINE, TUMOR; CELL PROLIFERATION; DIHYDROTESTOSTERONE; FINASTERIDE; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; HOMEODOMAIN PROTEINS; HUMANS; MUTATION; NITRILES; RECEPTORS, ANDROGEN; TOSYL COMPOUNDS;

EID: 79957449994     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.11.10.15187     Document Type: Article

References (26)

1. Russell DW, Wilson JD. Steroid 5α-reductase: Two genes/two enzymes. Annu Rev Biochem 1994; 63:25-61.
2. Dörsam J, Altwein J. 5α-Reductase inhibitor treatment of prostatic diseases: background and practical implications. Prostate Cancer Prostatic Dis 2009; 12:130-6.
3. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349:215-24. (Pubitemid 36859473)
4. Wang LG, Liu XM, Kreis W, Budman DR. Downregulation of prostate-specific antigen expression by finasteride through inhibition of complex formation between androgen receptor and steroid receptor-binding consensus in the promoter of the PSA gene in LNCaP cells. Cancer Res 1997; 57:714-9. (Pubitemid 27085656)
5. Lazier CB, Thomas LN, Douglas RC, Vessey JP, Rittmaster RS. Dutasteride, the dual 5α-reductase inhbitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line. Prostate 2004; 58:130-44. (Pubitemid 38160900)
6. Long BJ, Grigoryev DN, Nnane IP, Liu Y, Ling YZ, Brodie AM. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer. Cancer Res 2000; 60:6630-40.
7. Chhipa RR, Lee KS, Onate S, Wu Y, Ip C. Prx1 enhances androgen receptor function in prostate cancer cells by increasing receptor affinity to dihydrotestosterone. Mol Cancer Res 2009; 7:1543-52.
8. Shi XB, Ma AH, Xia L, Kung HJ, de Vere White RW. Functional analysis of 44 mutant androgen receptors from human prostate cancer. Cancer Res 2002; 62:1496-502. (Pubitemid 34407813)
9. Gottlieb B, Lehvaslaiho H, Beitel LK, Lumbroso R, Pinsky L, Trifiro M. The androgen receptor gene mutations database. Nucleic Acids Res 1998; 26:234-8. (Pubitemid 28291537)
10. Bergerat JP, Céraline J. Pleiotropic functional properties of androgen reeptor mutants in prostate cancer. Hum Mutat 2009; 30:145-57.
11. Yuan X, Balk SP. Mechanisms mediating androgen receptor reactivation after castration. Urol Oncol Orig Invest 2009; 27:36-41.
12. Steinkamp MP, O'Mahoney OA, Brogley M, Rehman H, LaPensee EW, Dhanasekaran S, et al. Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Res 2009; 69:4434-42.
13. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocrine Rev 2004; 25:276-308. (Pubitemid 38501396)
14. Luu-The V, Bélanger A, Labrie F. Androgen biosynthetic pathways in the human prostate. Best Pract Res Clin Endocrinol Metab 2008; 22:207-21. (Pubitemid 351611954)
15. Vis AN, Schröder FH. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways. BJU Int 2009; 104:438-48.
16. Masiello D, Cheng S, Bubley GJ, Lu ML, Balk SP. Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem 2002; 277:26321-6. (Pubitemid 34967123)
17. Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Issacs JT. Pharmacologic basis for the enhanced efficacy of dutasteride against prostate cancers. Clin Cancer Res 2006; 12:4072-9. (Pubitemid 44078095)
18. Suzuki R, Satoh H, Ohtani H, Hori S, Sawada Y. Saturable binding of finasteride to steroid 5α-reductase as determinant of nonlinear pharmacokinetics. Drug Metab Pharmacokinet 2010; 25:208-13.
19. Scholz MC, Jenrich RI, Strum SB, Johnson HJ, Guess BW. Intermittent use of testosterone inactivating pharmaceuticals using finasteride prolongs the time off period. J Urol 2006; 175:1673-8.
20. Eggener SE, Stern JA, Jain PM, Oram S, Ai J, Cai X, et al. Enhancement of intermittent androgen ablation by "off-cycle" maintenance with finasteride in LNCaP prostate cancer xenograft model. Prostate 2006; 66:495-502.
21. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LWK. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: Role of bone stromal cells. Int J Cancer 1994; 57:406-12. (Pubitemid 24168617)
22. Zhang H, Wu Y, Malewicz B, Lu J, Li S, Marshall J, et al. Augmented suppression of androgen receptor signaling by a combination of α-tocopheryl succinate and methylseleninic acid. Cancer 2006; 107:2942-8. (Pubitemid 44937050)
23. 70, for the androgen receptor in human prostate cells. Proc Natl Acad Sci USA 1996; 93:5517-21.
24. Kokontis J, Ito K, Hipakka RA, Liao S. Expression and function of normal and LNCaP androgen receptors in androgen-insensitive human prostatic cancer cells. Altered hormone and antihormone specificity in gene transactivation. Receptor 1991; 1:271-9.
25. Wu Y, Fabritius M, Ip C. Chemotherapeutic sensitization by endoplasmic reticulum stress: Increasing the efficacy of taxane against prostate cancer. Cancer Biol Ther 2009; 8:146-52.
26. Li S, Zhou Y, Wang R, Zhang H, Dong Y, Ip C. Selenium sensitizes MCF-7 breast cancer cells to doxorubicin-induced apoptosis through modulation of phospho-Akt and its downstream substrates. Mol Cancer Ther 2007; 6:1031-8. (Pubitemid 46554573)